A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

• Register: ClinicalTrials.gov
• Last refreshed on: 19 October 2017
• Main ID: NCT00443534
• Date of registration: 02/03/2007
• Prospective Registration: No
• Primary sponsor: Pfizer
• Public title: A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
• Scientific title: A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
• Date of first enrolment: May 2006
• Target sample size: 123
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT00443534
• Study type: Interventional
• Phase: N/A

Countries of recruitment

Canada, France, Germany, Italy, Spain, United Kingdom, United States

Contacts

• Name: Pfizer CT.gov Call Center
• Affiliation: Pfizer

Key inclusion & exclusion criteria

Inclusion Criteria:

- Participation in a previous SU011248 protocol and are judged by the investigator to
have the potential to derive clinical benefit by remaining on SU011248 after the prior
protocol ends.

Exclusion Criteria:

- Severe acute or chronic medical or psychiatric condition, or laboratory abnormality
that may increase the risk associated with study participation or study drug
administration, or may interfere with the interpretation of study results, and in the
judgment of the investigator would make the patient inappropriate for entry into this
study.



Age minimum: 18 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Neoplasms

Intervention(s)

Drug: SU011248

Primary Outcome(s)

Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) [Time Frame: Baseline up to Day 28 after last dose of study treatment]

Secondary ID(s)

A6181078

Source(s) of Monetary Support

Please refer to primary and secondary sponsors

Results

• Results available: Yes
• Date Posted: 24/05/2013
• URL: https://clinicaltrials.gov/ct2/show/results/NCT00443534